230 related articles for article (PubMed ID: 23252711)
1. Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
Hole AJ; Baumli S; Shao H; Shi S; Huang S; Pepper C; Fischer PM; Wang S; Endicott JA; Noble ME
J Med Chem; 2013 Feb; 56(3):660-70. PubMed ID: 23252711
[TBL] [Abstract][Full Text] [Related]
2. Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities.
Shao H; Shi S; Huang S; Hole AJ; Abbas AY; Baumli S; Liu X; Lam F; Foley DW; Fischer PM; Noble M; Endicott JA; Pepper C; Wang S
J Med Chem; 2013 Feb; 56(3):640-59. PubMed ID: 23301767
[TBL] [Abstract][Full Text] [Related]
3. Halogen bonds form the basis for selective P-TEFb inhibition by DRB.
Baumli S; Endicott JA; Johnson LN
Chem Biol; 2010 Sep; 17(9):931-6. PubMed ID: 20851342
[TBL] [Abstract][Full Text] [Related]
4. Molecular principle of the cyclin-dependent kinase selectivity of 4-(thiazol-5-yl)-2-(phenylamino) pyrimidine-5-carbonitrile derivatives revealed by molecular modeling studies.
Kong X; Sun H; Pan P; Tian S; Li D; Li Y; Hou T
Phys Chem Chem Phys; 2016 Jan; 18(3):2034-46. PubMed ID: 26686753
[TBL] [Abstract][Full Text] [Related]
5. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity.
Wang S; Meades C; Wood G; Osnowski A; Anderson S; Yuill R; Thomas M; Mezna M; Jackson W; Midgley C; Griffiths G; Fleming I; Green S; McNae I; Wu SY; McInnes C; Zheleva D; Walkinshaw MD; Fischer PM
J Med Chem; 2004 Mar; 47(7):1662-75. PubMed ID: 15027857
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents.
Shao H; Foley DW; Huang S; Abbas AY; Lam F; Gershkovich P; Bradshaw TD; Pepper C; Fischer PM; Wang S
Eur J Med Chem; 2021 Mar; 214():113244. PubMed ID: 33581551
[TBL] [Abstract][Full Text] [Related]
7. Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.
Sonawane YA; Taylor MA; Napoleon JV; Rana S; Contreras JI; Natarajan A
J Med Chem; 2016 Oct; 59(19):8667-8684. PubMed ID: 27171036
[TBL] [Abstract][Full Text] [Related]
8. Novel, selective CDK9 inhibitors for the treatment of HIV infection.
Németh G; Varga Z; Greff Z; Bencze G; Sipos A; Szántai-Kis C; Baska F; Gyuris A; Kelemenics K; Szathmáry Z; Minárovits J; Kéri G; Orfi L
Curr Med Chem; 2011; 18(3):342-58. PubMed ID: 21143121
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
Jing L; Tang Y; Xiao Z
Bioorg Med Chem Lett; 2018 May; 28(8):1386-1391. PubMed ID: 29550093
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.
Wang B; Wu J; Wu Y; Chen C; Zou F; Wang A; Wu H; Hu Z; Jiang Z; Liu Q; Wang W; Zhang Y; Liu F; Zhao M; Hu J; Huang T; Ge J; Wang L; Ren T; Wang Y; Liu J; Liu Q
Eur J Med Chem; 2018 Oct; 158():896-916. PubMed ID: 30253346
[TBL] [Abstract][Full Text] [Related]
11. The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508.
Baumli S; Hole AJ; Noble ME; Endicott JA
ACS Chem Biol; 2012 May; 7(5):811-6. PubMed ID: 22292676
[TBL] [Abstract][Full Text] [Related]
12. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.
Albert TK; Rigault C; Eickhoff J; Baumgart K; Antrecht C; Klebl B; Mittler G; Meisterernst M
Br J Pharmacol; 2014 Jan; 171(1):55-68. PubMed ID: 24102143
[TBL] [Abstract][Full Text] [Related]
13. Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma.
Czudor Z; Balogh M; Bánhegyi P; Boros S; Breza N; Dobos J; Fábián M; Horváth Z; Illyés E; Markó P; Sipos A; Szántai-Kis C; Szokol B; Őrfi L
Bioorg Med Chem Lett; 2018 Feb; 28(4):769-773. PubMed ID: 29329658
[TBL] [Abstract][Full Text] [Related]
14. Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9.
Ayaz P; Andres D; Kwiatkowski DA; Kolbe CC; Lienau P; Siemeister G; Lücking U; Stegmann CM
ACS Chem Biol; 2016 Jun; 11(6):1710-9. PubMed ID: 27090615
[TBL] [Abstract][Full Text] [Related]
15. Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9.
Phillipson LJ; Segal DH; Nero TL; Parker MW; Wan SS; de Silva M; Guthridge MA; Wei AH; Burns CJ
Bioorg Med Chem; 2015 Oct; 23(19):6280-96. PubMed ID: 26349627
[TBL] [Abstract][Full Text] [Related]
16. Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents.
Wang S; Griffiths G; Midgley CA; Barnett AL; Cooper M; Grabarek J; Ingram L; Jackson W; Kontopidis G; McClue SJ; McInnes C; McLachlan J; Meades C; Mezna M; Stuart I; Thomas MP; Zheleva DI; Lane DP; Jackson RC; Glover DM; Blake DG; Fischer PM
Chem Biol; 2010 Oct; 17(10):1111-21. PubMed ID: 21035734
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of dinaciclib and CAN508 hybrids as CDK inhibitors.
Odeh DM; Allam HA; Baselious F; Mahmoud WR; Odeh MM; Ibrahim HS; Abdel-Aziz HA; Mohammed ER
Drug Dev Res; 2024 May; 85(3):e22193. PubMed ID: 38685605
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological targeting of CDK9 in cardiac hypertrophy.
Krystof V; Chamrád I; Jorda R; Kohoutek J
Med Res Rev; 2010 Jul; 30(4):646-66. PubMed ID: 19757441
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and anticancer evaluation of selective 2,4-disubstituted pyrimidine CDK9 inhibitors.
Xu Z; Zhang B; Liu Z; Gou S
Eur J Med Chem; 2022 Dec; 244():114875. PubMed ID: 36332552
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement.
Barlaam B; De Savi C; Dishington A; Drew L; Ferguson AD; Ferguson D; Gu C; Hande S; Hassall L; Hawkins J; Hird AW; Holmes J; Lamb ML; Lister AS; McGuire TM; Moore JE; O'Connell N; Patel A; Pike KG; Sarkar U; Shao W; Stead D; Varnes JG; Vasbinder MM; Wang L; Wu L; Xue L; Yang B; Yao T
J Med Chem; 2021 Oct; 64(20):15189-15213. PubMed ID: 34647738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
